Brace for more dour figures on venture investment in biotech. Despite some bright spots in life sciences venture investing, a new study finds that VC players in biotech and devices might struggle to sustain investment levels. And one of the few consolation prizes for the companies that won venture deals is that valuations inched up in 2012.
To read the original article: Analysis: 2012 life sciences VC fundraising and new bets shrivel - FierceBiotech
